Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

74.17 +1.25 (+1.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 411,329
Open 73.09
Bid (Size) 71.00 (200)
Ask (Size) 85.00 (100)
Prev. Close 72.92
Today's Range 72.80 - 76.14
52wk Range 38.51 - 76.81
Shares Outstanding 34,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Growth Momentum and Technical Setup ↗
Discover Tarsus Pharmaceuticals (TARS), a high-growth stock with strong fundamentals and a bullish technical setup poised for a potential breakout. 
Via Chartmill
News headline image
Tarsus to Participate in Upcoming Investor Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Performance

YTD
+34.5%
+34.5%
1 Month
+1.7%
+1.7%
3 Month
+35.8%
+35.8%
6 Month
+64.8%
+64.8%
1 Year
+66.2%
+66.2%

More News

Read More
News headline image
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
Via Benzinga
News headline image
An Overview of Tarsus Pharmaceuticals's Earnings ↗
Via Benzinga
News headline image
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase ↗
Via The Motley Fool
News headline image
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗
Via The Motley Fool
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
3 Biotech Catalysts Present Major Opportunity ↗
Via MarketBeat
News headline image
Top 2 Health Care Stocks That May Fall Off A Cliff In August ↗
Via Benzinga
News headline image
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
Via Benzinga
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know ↗
Via Benzinga
News headline image
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal ↗
Via Benzinga
News headline image
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Would Mark Minervini consider TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) a top stock pick? ↗
Via Chartmill
News headline image
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Why Mark Minervini may look into TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) ↗
Via Chartmill

Frequently Asked Questions

Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?
Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market
What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?
The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 74.17
When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 11/17/25 04:00 PM ET
What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 2.54B
How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?
Tarsus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.